Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: Subanalysis of the FIN-RACo trial

Annals of the Rheumatic Diseases

Volumn 72, Issue 5, 2013, Pages 786-788

  Rantalaiho, Vappu Marianna ^a   Kautiainen, Hannu ^b   Korpela, Markku ^a   Hannonen, Pekka J ^c   Leirisalo Repo, Marjatta ^b   Möttönen, Timo ^d  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LETTER; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYCHLOROQUINE; METHOTREXATE; SULFASALAZINE; TREATMENT OUTCOME;

EID: 84875964454     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202737     Document Type: Letter

References (10)

1. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
3. Deighton C, O'ahony R, Tosh J, et al. Management of rheumatoid arthritis: summary of NICE guidance. BMJ 2009;338:b702.
4. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
5. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73. (Pubitemid 29219206)
6. Rheumatoid arthritis (online). Current Care Guideline. Article in Finnish. Working group set up by the Finnish Medical Society Duodecim and the Finnish Society for Rheumatology. Helsinki: The Finnish Medical Society Duodecim, 2003 (accessed 13 August 2009), 2009. http://www.kaypahoito.fi.
7. de Jong PH, Hazes JM, Barendregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 2013;72:72-8.
8. Leirisalo-Repo M, Kautiainen H, Laasonen L, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis 2012. doi:10.1136/annrheumdis-2012-201365
9. Rezaei H, Saevarsdottir S, Forslind K, et al. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 2012;71:186-91.
10. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a Randomized Trial. Ann Intern Med 2012;156:329-39.